Asia Pacific Next Generation Sequencing (NGS) Market Size, Share, Growth, Trends, and Industry Analysis: By Product (Consumables, Instruments, Software, and Services), By Technology (Whole Targeted Re-sequencing, Whole Genome Sequencing, Transcriptome (RNA-Seq), Whole Exome Sequencing, De Novo Sequencing, Chip Sequencing, Methylation Sequencing, and Others), By Workflow (Pre-Sequencing, Sequencing, NGS Data Analysis), By Application (Diagnostics, Drug Discovery & Development, Biomarker Discovery, Agriculture & Animal Health Research, and Personalised Medicine), By End User (Academic Institutes & Research Centers, Hospital/Clinical Laboratories, Biotech/Pharmaceuticals Companies, and Others), and Country Forecast 2019-2030

Asia Pacific next generation sequencing market size was valued at US$ 6,783.2 million in 2023 and is anticipated to grow at a CAGR of 17.1 % over 2024-2030. Next-generation sequencing (NGS), also known as high-throughput sequencing, is a revolutionary technology used in genomics to determine the precise order of nucleotides (adenine, cytosine, guanine, and thymine) in a DNA or RNA molecule. NGS methods enable researchers to sequence large quantities of DNA or RNA simultaneously, making it faster, more cost-effective, and highly scalable compared to traditional Sanger sequencing methods.

Neurological disorders are significant drivers of growth and revenue in the Asia Pacific next-generation sequencing (NGS) market. NGS technologies are increasingly employed in neurogenetics research to elucidate the genetic underpinnings of various neurological conditions, including Alzheimer's disease, Parkinson's disease, autism spectrum disorders, and rare genetic disorders like Huntington's disease. These studies have led to the identification of novel genetic mutations and risk factors, enhancing our understanding of disease mechanisms and potential therapeutic targets. Moreover, agriculture and animal health research significantly drive revenues in the next-generation sequencing (NGS) market.

NGS technologies have been instrumental in advancing agricultural genomics, allowing researchers to study crop genetics, livestock genomes, and microorganisms in agricultural ecosystems. This research has led to the development of improved crop varieties, disease-resistant livestock breeds, and sustainable farming practices. Additionally, in the animal health sector, NGS is used for disease diagnosis, monitoring genetic diversity, and studying zoonotic diseases. As global concerns about food security, sustainable agriculture, and animal health continue to grow, the demand for NGS-based solutions in these fields rises, contributing to market growth and innovation in agriculture and animal health research.

However, many countries in the Asia-Pacific region may lack the necessary infrastructure and expertise in genomics and bioinformatics, which can hinder NGS adoption and utilization. Moreover, Budget limits for end users in developing countries also retrain the market growth. Meanwhile, rising government investments in these countries can create significant growth opportunities. Furthermore, several key market players are developing innovative solutions to cater to the medical industries. For instance, in March 2023, Illumina and GenoScreen have introduced a new package that combines products from Illumina with the GenoScreen Deeplex Myc-TB assay, a next-generation sequencing (NGS)-based test for Tuberculosis (TB).

Key Developments:      

• In April 2022, PHC Corporation launched next-generation sequencer, the DNBSEQ series in Japan.
• In May 2022, Genes2Me launched a wide range of Next-Generation Sequencing (NGS)-based panels for oncology, personalized medicine, and hereditary diseases in India.